Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab and Tofacitinib in Moderately to Severely Active Ulcerative Colitis
NCT06095128Phase 4Active, not recruiting
- Sponsor
- Takeda
- Start
- Jun 2024
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 4 trial of vedolizumab, tofacitinib oral solution in ulcerative colitis (UC), sponsored by Takeda. Started Jun 2024; status: active, not recruiting.
02
Drugs
vedolizumabtofacitinib oral solution
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06095128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06095128.